VALLEY COTTAGE, New York, September 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) will hold a conference call today, September 11, 2007, at 8:30 a.m. EDT to discuss the Phase IIb clinical trial of Bicifadine for the treatment of diabetic neuropathic pain that was initiated yesterday.
Hosting the call will be Ron Bentsur, XTL's Chief Executive Officer. Participating on the call will be two distinguished members of the diabetic neuropathic pain clinical community: Dr. Christine Sang, Director of Translational Pain Research at the Brigham and Women's Hospital, Harvard Medical School, and Chair of XTL's Scientific Advisory Board; and Dr. Andrew Boulton, Professor of Medicine at the Diabetes Research Institute, University of Miami, and at the University of Manchester in the United Kingdom, Chair of the American Diabetes Association Foot Care Interest Group, and a co-lead investigator in the Bicifadine study.
In order to participate in the conference call, please call +1-877-502-9272 (in the United States), +1-913-981-5581 (outside the United States), call in passcode: 2040477. An audio recording of the conference call will be available for replay by calling +1-888-203-1112 (in the United States), +1-719-457-0820 (outside the United States), replay passcode 2040477, for a period of 45 days after the call.
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor,
for the treatment of diabetic neuropathic pain. XTL is also developing
several novel pre-clinical hepat
|SOURCE XTL Biopharmaceuticals Ltd|
Copyright©2007 PR Newswire.
All rights reserved